Engineered Microbial Lipase: GHE | July 2026

Introduction:

Pancreatic enzyme replacement therapy (PERT) is the standard treatment for exocrine pancreatic insufficiency (EPI) but is currently derived exclusively from porcine pancreatic extracts, requiring multiple capsules and often providing suboptimal fat digestion. This study developed and evaluated an engineered recombinant microbial lipase as a potential next-generation alternative to conventional PERT.

Why was this study needed?

• Current porcine-derived PERT has variable efficacy and requires a high pill burden.
• Enteric-coated pancreatic lipase may be delayed or inactivated in patients with acidic duodenal pH.
• There is a need for recombinant, non-animal enzyme therapies with improved gastric stability.
• Microbial lipases offer greater acid stability and do not require colipase for activity.
• More effective treatments could improve nutrition and quality of life in patients with EPI.

Results:

• The engineered microbial lipase demonstrated excellent stability under gastric and intestinal conditions and effectively hydrolyzed a broad range of dietary fats without requiring enteric coating.
• In a pancreatic duct ligation minipig model, the recombinant enzyme restored fat absorption to levels comparable with porcine PERT while requiring approximately 10-fold less protein by mass.
• In a Phase 1 proof-of-concept clinical trial, the recombinant lipase showed a favorable safety profile and significantly improved fat absorption in patients with EPI, supporting further clinical development.

Clinical Impact:

This study introduces a promising recombinant microbial alternative to porcine-derived PERT. A more potent, acid-stable enzyme could substantially reduce pill burden, improve fat digestion, and overcome many limitations of current enzyme replacement therapy. Larger Phase II and III trials will be required to confirm long-term efficacy and safety.

Bottom Line:

An engineered recombinant microbial lipase demonstrated superior biochemical stability, restored fat absorption with much lower dosing than conventional porcine PERT in preclinical studies, and improved fat digestion in early clinical testing. This technology has the potential to become the next generation of pancreatic enzyme replacement therapy for exocrine pancreatic insufficiency.